Edition:
India

Ajanta Pharma Ltd (AJPH.NS)

AJPH.NS on National Stock Exchange of India

1,560.05INR
19 Jan 2018
Change (% chg)

Rs26.85 (+1.75%)
Prev Close
Rs1,533.20
Open
Rs1,533.25
Day's High
Rs1,567.00
Day's Low
Rs1,533.25
Volume
158,597
Avg. Vol
278,885
52-wk High
Rs1,852.95
52-wk Low
Rs1,120.05

Chart for

About

Ajanta Pharma Limited is a holding company. The Company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and... (more)

Overall

Beta: 1.44
Market Cap(Mil.): Rs103,901.10
Shares Outstanding(Mil.): 88.01
Dividend: 7.00
Yield (%): 1.10

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Ajanta Pharma's Vice-Chairman​ Purushottam B. Agrawal Resigns

* SAYS ‍ PURUSHOTTAM B. AGRAWAL RESIGNS AS VICE-CHAIRMAN​ Source text: http://bit.ly/2kuqxWC Further company coverage:

15 Dec 2017

BRIEF-India's Ajanta Pharma launches clonidine hydrochloride extended release tablets in U.S.

* Ajanta Pharma announces approval & launch of clonidine hydrochloride extended release tablets

21 Nov 2017

BRIEF-India's Ajanta Pharma Sept-qtr consol profit rises marginally

* Sept quarter consol net profit 1.32 billion rupees versus 1.31 billion rupees year ago

31 Oct 2017

BRIEF-India's Ajanta Pharma gets final approval for Entacapone tablets from U.S. FDA

* Says received the final approval for Entacapone tablets from US FDA

04 Sep 2017

BRIEF-Ajanta Pharma says U.S. unit launches eletriptan hydrobromide tablets

* Says launched eletriptan hydrobromide tablets in US market through our wholly owned subsidiary, Ajanta Pharma USA Inc. Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-India's Ajanta Pharma June-qtr profit falls

* June quarter profit 947.9 million rupees versus 1.20 billion rupees year ago

09 Aug 2017

Earnings vs. Estimates